Chary López-Pedrera

Ex vivo JAK and TNF inhibitor–modulated immune signatures guide first-line therapy selection in rheumatoid arthritis

Background Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease for which selecting the most appropriate first targeted therapy remains challenging. We integrated ex vivo immune-cell functional assays, targeted proteomics, clinical outcomes, and a three-dimensional (3D...